The MPS Antibody Discovery platform overcomes three key barriers to enable success; presenting native epitopes, making the target highly immunogenic, and generating MAbs against diverse epitopes. Optimizing for antigen and a strategic immunization are critically important for downstream success. The MPS Antibody Discovery platform overcomes challenges associated with membrane proteins such as poor expression, trafficking, toxicity, and preservation of native conformation. Specialized tools, technology, and expertise includes proprietary expression vectors, targeted mutagenesis strategies, and premium reagents for exceptional outcomes. As the inventors of Lipoparticles, rest assured that your project begins with the highest quality antigen available for immunization and discovery. Our innovative immunization protocols may include the use of divergent species, DNA, mRNA, and Lipoparticles. This system is proven to elicit a robust, diverse, and focused immune responses on relevant extracellular epitopes. We routinely isolate high-affinity, humanized mAbs against highly conserved membrane protein targets, with desirable characteristics including state-specific binding and functional activity.

The MPS platform delivers fully humanized MAbs. Healthy, outbred, wild-type chickens are excellent immunization hosts, producing robust immune responses and offering excellent opportunities for MAb diversity while overcoming homology challenges associated with mammalian hosts. Chicken antibody frameworks are highly amenable to humanization. With our Humanized Chicken Antibody Discovery technology (hCAT), antibody CDR’s from responsive chickens are humanized prior to the creation of immune libraries used for phage panning. Hits isolated during screening are fully humanized, eliminating the time and cost required for downstream engineering. The result is high affinity, fully humanized MAbs ready for preclinical characterization.

Alternatively, we are a Certified Service Provider of Alloy Therapeutics, offering immunization in ATX-Gx^TM transgenic, immunocompetent mice which produce human antibodies.

The final deliverable of an MPS Antibody Discovery project is usually a panel of highly specific, diverse, and functional MAbs that meet the customer’s specifications. Using our MPS Antibody Discovery platform, we have a very high success rate (>95%) in delivering such MAb panels. In addition to the final deliverable, customers receive 4 progress reports during their MPS project:

1. Target Expression Report – Summarizes target expression after engineering to validate immunization, panning, and screening constructs, and sufficient target incorporation into Lipoparticles


2. Serum Reactivity Report – Summarizes the immune response of each animal to the target protein


3. Clone Screen Report – Summarizes MAb selection results and the diversity of discovered MAbs


4. MAb Validation and Sequence Report –Sequences are reported with a summary of target-specific binding validation by flow cytometry in final preferred format (eg., IgG). Purified, ready to use IgG may be provided for customer evaluation.